Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
⁶⁸Ga-FC516 in Healthy Subjects and Prostate Cancer Patients
NCT07468708Phase 1Recruiting
- Sponsor
- FindCure Biosciences
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-FC516 in prostate cancer (PCa) (2 arms), sponsored by FindCure Biosciences. Primary endpoints: Frequency of adverse events (AEs) and serious adverse events (SAEs) at 6 months, Standard uptake value of tumors at 6 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
68Ga-FC516
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07468708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468708.